Business
HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®
HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa&#x...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n \n Private payer health plan coverage in\n \n Canada\n \n for Vascepa is expected to reach more than 80% by the end of\n \n February 2021\n \n , up from 50% in\n \n November 2020\n \n \n \n \n \n \n \n Coverage effective for statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetics with risk factors\n \n \n \n \n \n \n Active negotiations have also begun with the pan-Canadian Pharmaceutical Alliance (pCPA) for reimbursement of Vascepa by publicly funded health plans\n \n \n \n \n \n \n TORONTO\n \n ,\n \n Feb. 16, 2021\n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, expects that by the end of\n \n February 2021\n \n , private payer health plans covering more than 80% of the privately insured lives in\n \n Canada\n \n will have agreed to provide reimbursement for Vascepa.\n \n \n Vascepa is approved for use in\n \n Canada\n \n to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.\n \n \n \"In a little more than a year since Vascepa's approval by Health Canada, we will have reached reimbursement levels for the drug for the vast majority of all privately covered lives in\n \n Canada\n \n ,\" said\n \n Gilbert Godin\n \n , CEO of HLS. \"Vascepa reduces the risk of major cardiac events for which no other drug is currently indicated in this patient population in\n \n Canada\n \n and it is supported by substantial evidence ...